Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab in advanced high-grade neuroendocrine carcinoma (NEC G3) after chemotherapy
2016-004373-40Phase 2Completed
- Sponsor
- University Medical Center Mainz
- Start
- May 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in neuroendocrine carcinoma (NEC), sponsored by University Medical Center Mainz. Primary endpoint: Disease control rate at 16 weeks. Started May 2017; status: completed.
02
Drugs
avelumab
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2016-004373-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004373-40.